Advanced Enzyme Technologies

ADVENZYMES · NSE

— · —

₹315.1

Closing price — 31 Jul 2026

Market cap ₹3,517 Cr · EPS ₹9.94

Valuation

Blended fair value using DCF and peer comparison methods.

Intrinsic Value

₹346

+9.8% vs ₹315

Fairly valued

UndervaluedFair valueOvervalued

DCF

₹166

Peer methods

₹526

Intrinsic value

₹346

DCF discounts future cash flows to present value. Peer methods compare against sector multiples. Averaging both reduces the limitations of each method alone.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Advanced Enzyme Technologies ADVENZYMES · you	₹3,517 Cr	20.8×	2.2×	—	10.3%	22.6%	11.3%
Sector median	—	32.5×	4.1×	26.5×	15.6%	19.6%	14.0%
Ajanta Pharmaceuticals AJANTPHARM	₹27,006 Cr	34.9×	8.1×	28.3×	23.3%	19.4%	13.4%
Acutaas Chemicals ACUTAAS	₹26,189 Cr	73.8×	15.8×	54.5×	21.5%	26.6%	29.5%
Pfizer PFIZER	₹21,129 Cr	29.1×	5.0×	24.7×	17.2%	28.7%	1.3%
Piramal Pharma PPLPHARMA	₹19,898 Cr	—	2.7×	33.4×	-4.0%	-3.7%	7.8%
Eris Lifesciences ERIS	₹19,020 Cr	30.2×	4.8×	18.1×	15.9%	19.8%	22.9%
Onesource Specialty Pharma ONESOURCE	₹18,447 Cr	—	3.4×	64.6×	-1.3%	-5.2%	232.4%
NATCO Pharma NATCOPHARM	₹15,503 Cr	11.0×	1.7×	10.9×	15.4%	34.8%	14.6%
Jubilant Pharmova JUBLPHARMA	₹15,442 Cr	38.2×	2.1×	15.3×	5.6%	4.8%	9.6%

Peer comparison verdict

Advanced trades at a discount to sector peers on P/E (20.8× vs median 32.5×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.

Business quality

Valuation

P/E ratio

20.8×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

10.3%

ROCE

11.6%

ROA

—

Growth

Revenue CAGR (3yr)

11.3%

EPS CAGR (3yr)

16.9%

Efficiency

Asset turnover

—

FCF yield

3.0%

Dividend yield

0.4%

Liquidity & Solvency

Debt / Equity

—

Debt / EBITDA

—

Interest coverage

76.2×

Current ratio

9.78×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹746 Cr

Net profit

₹169 Cr

Operating margin

—

Net margin

22.6%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

₹156.78 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

₹104.55 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹8 Cr

Equity

₹1,632 Cr

Debt / Equity

0.00×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

43.3%

+0.2 pp QoQ

FII

25.5%

-0.3 pp QoQ

DII

5.4%

-0.1 pp QoQ

Retail

25.9%

Trend over time (%)

Quarterly data

Category	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Change (YoY)
Promoter	46.5%	45.9%	43.6%	43.5%	43.0%	43.0%	42.9%	43.1%	43.1%	43.1%	43.0%	43.3%	+0.2 ppYoY
FII (Foreign)	21.9%	22.3%	22.5%	23.0%	12.0%	12.6%	12.6%	11.9%	23.4%	25.4%	25.9%	25.5%	+13.6 ppYoY
DII (Domestic)	7.6%	6.5%	7.0%	7.6%	8.1%	8.0%	8.2%	8.2%	8.4%	6.4%	5.5%	5.4%	-2.8 ppYoY
Retail	24.0%	25.3%	26.9%	25.9%	36.9%	36.4%	36.3%	36.8%	25.0%	25.1%	25.6%	25.9%	-11.0 ppYoY

Signals from the trend

📉

PromoterDown 3.3pp — worth monitoring for further declines

📈

FIINet buyers (+3.6pp) — foreign institutional interest is growing

📉

DIINet sellers (2.2pp) — domestic funds are reducing

Mixed signals — FII buying on the positive side, but promoter selling adds uncertainty.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.